Pharmacogenetic Testing for 5-FU Saves Lives and Money

Prospective screening for a genetic variant of DPD, an enzyme that catabolizes 5-FU, reduces mortality from 10% to 0% in patients with this variant and is cost-effective. Dr David Kerr is all for it.

Source: Medscape Oncology - February 5, 2016 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts